Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Support Care Cancer. 2014 Apr 15;22(9):2535–2545. doi: 10.1007/s00520-014-2204-5

Table 1.

Demographic and disease characteristics

Characteristics BC (n=68) NC (n=60)

Age (years)
 Mean (SD) 51.3 (9.1) 52.4 (9.4)
 Range 31 – 76 29 – 81

Body mass index (BMI, kg/m2)
 Mean (SD) 27.6 (7.4) 25.9 (7.0)
 Range 19.3 – 61.9 19.1 – 56.7

Race [n (%)]
 Caucasian 60 (88.2) 51 (85.0)
 Non-Caucasian 8 (11.8) 9 (15.0)

Education [n (%)]
 Below completed college 32 (47.1) 21 (35.0)
 Completed college and above 36 (52.9) 39 (65.0)

Marital status [n (%)]
 Never married 3 (4.4) 7 (11.7)
 Divorced/separated/widowed 19 (27.9) 12 (20.0)
 Married 46 (67.7) 41 (68.3)

Household annual income [n (%)]
 ≤ $100,000 25 (36.8) 21 (35.0)
 > $100,000 43 (63.2) 39 (65.0)

Baseline menopausal status [n (%)]
 pre-menopause 28 (41.2) 20 (33.9)
 peri-menopause 8 (11.8) 8 (13.6)
 post-menopause 27 (39.7) 22 (37.3)
 hysterectomy 5 (7.3) 9 (15.3)
 Not available 0 1

Cancer stage [n (%)] -
 Stage I 19 (28.4)
 Stage II 27 (40.3)
 Stage III 21 (31.3)
 Not available 1

Surgery type -
 Lumpectomy 31 (45.6)
 Mastectomy 31 (45.3)
 Double mastectomy 3 (4.4)
 No surgery before Chemotherapy 3 (4.4)
 Not available 0

Days between surgery and start of chemotherapy -
 Available (n=47)
  Mean (SD) 42.0 (16.7)
  Range 14 – 106
 Not available (n=21) -

Chemotherapy regimen [n (%)] -
 AC 13 (19.7)
 AC followed by docetaxel 6 (9.1)
 AC followed by paclitaxel 34 (51.5)
 Other 13 (19.7)
 Not available 2

Note: BC= women with breast cancer, NC=cancer-free controls. No significant differences between the two groups in age, BMI, race, education, marital status, household annual income and baseline menopause status (all p’s>0.2). AC = Doxorubicin + Cyclophosphamide.

HHS Vulnerability Disclosure